FBInvestor
Stocks / Karyopharm Therapeutics Inc
Institutional Ownership

Karyopharm Therapeutics Inc

CUSIP 48576U205COM NEWKPTIQ1 2026

13D / 13G Filings
12
Schedule 13D/13G on record
Beneficial Filers
10
Distinct reporting persons
Largest Stake
13.8%
Max % of class reported
Institutional Holders
73
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

12 filings · latest Feb 17, 2026

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Feb 17, 2026T. Rowe Price Investment Management, Inc.13G/A11.8%2.24MSEC
2Feb 12, 2026Adage Capital Management, L.P.13G/A2.4%436.7KSEC
3Feb 10, 2026Integrated Core Strategies (Us) LLC13G11.0%1.01MSEC
4Jan 29, 2026Affinity Asset Advisors, LLC13G/A8.6%1.71MSEC
5Nov 14, 2025Highbridge Capital Management, LLC13G/A4.9%650.0KSEC
6Nov 7, 2025T. Rowe Price Investment Management, Inc.13G/A13.8%2.30MSEC
7Nov 3, 2025J. Wood Capital Advisors LLC13G/A5.0%1.00MSEC
8Oct 30, 2025The Vanguard Group13G/A4.7%408.2KSEC
9Oct 17, 2025Opaleye Management Inc.13G9.5%1.57MSEC
10Aug 14, 2025T. Rowe Price Investment Management, Inc.13G8.4%728.8KSEC

2 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Karyopharm Therapeutics Inc.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →